Treatment(s) now being considered-Chemotherapy - Page 15 of 16 Posts on Medivizor
Navigation Menu

Treatment(s) now being considered-Chemotherapy Posts on Medivizor

Phase I trial to determine the safety of a new anti-cancer drug: PD 0332991

Phase I trial to determine the safety of a new anti-cancer drug: PD 0332991

Posted by on Mar 7, 2013 in Colorectal cancer | 0 comments

In a nutshell This article presents the results from the first human trial of PD 0332991, a new anti-cancer drug. The main objective of the study was to determine the safety and recommended dose for further testing. Results warrant further studies and revealed that neutropenia (low white cell count) was the main side effect. Some background Cells...

Read More

Metastatic colorectal cancer: the benefit of combining cetuximab with chemotherapy

Metastatic colorectal cancer: the benefit of combining cetuximab with chemotherapy

Posted by on Mar 5, 2013 in Colorectal cancer | 0 comments

In a nutshell The present study investigated if patients with spread colorectal cancer that have mutations in the KRAS gene benefit from Cetuximab treatment. Some background Cancer that originates in the colon or rectum (parts of the intestine) is called colorectal cancer (CRC). If the cancer has spread from its original location, beyond the...

Read More

Comparison of two surgical techniques for the treatment of pseudomyxoma peritonei

Comparison of two surgical techniques for the treatment of pseudomyxoma peritonei

Posted by on Mar 4, 2013 in Colorectal cancer | 1 comment

In a nutshell The present study compared the efficacy of two surgical techniques to treat pseudomyxoma peritonei (PMP): debulking and cytoreduction. Cytoreductive surgery achieved better surgical results and yielded higher 3- and 5-year survival rates, compared with debulking. Some background PMP is a rare condition caused by the production of...

Read More

Well-timed Docetaxel (Taxotere) therapy offers the best results in treating hormone-refractory prostate cancer

Well-timed Docetaxel (Taxotere) therapy offers the best results in treating hormone-refractory prostate cancer

Posted by on Mar 3, 2013 in Prostate cancer | 0 comments

In a nutshell This article reports the results of recent studies involving the drug Docetaxel (Taxotere). The drug did not improve overall survival when added to androgen-deprivation therapy. Smaller doses given in shorter treatment cycles were found to be easier to tolerate and more effective.   Some background Prostate cancer grows in...

Read More

Benefits of postoperative chemotherapy vary according to breast cancer type

Benefits of postoperative chemotherapy vary according to breast cancer type

Posted by on Feb 25, 2013 in Breast cancer | 0 comments

In a nutshell This study questioned the benefit of adding chemotherapy to postoperative hormonal treatment in the case of lobular breast cancer. Their findings were that chemotherapy seems to offer no additional beneficial effects in women with lobular breast cancer receiving hormonal therapy. Some background There are two main types of breast...

Read More

Risks versus benefit of the ‘HIPEC’ treatment for peritoneal metastases due to colorectal cancer

Risks versus benefit of the ‘HIPEC’ treatment for peritoneal metastases due to colorectal cancer

Posted by on Feb 24, 2013 in Colorectal cancer | 0 comments

Colorectal cancer (CRC) often presents with peritoneal metastases, which have a poor outcome. This means that cancer cells have spread from the colon, appendix, or rectum to the peritoneum (a sheath that covers the abdominal organs). This article argues the pros and cons of a combined treatment for patients with peritoneal metastases from CRC. This...

Read More

Comparing the benefits of two drug combinations as adjuvant chemotherapy for patients with stage III colon cancer

Posted by on Feb 24, 2013 in Colorectal cancer | 0 comments

In a nutshell The present study compared the survival benefits of two drug combinations used for adjuvant chemotherapy: Capecitabine/Oxaliplatin (Xelox) versus Fluorouracil/Folinic Acid (FU/FA). The study found Xelox to be a superior therapy for stage III colon cancer. Some background Stage III colon cancer is cancer...

Read More

What is the preferred duration of chemotherapy? – A review of clinical trials

What is the preferred duration of chemotherapy? – A review of clinical trials

Posted by on Feb 24, 2013 in Breast cancer | 0 comments

The aim of this paper was to identify if a longer course of chemotherapy was better than a short course. The authors look at how long patients survived with metastatic breast cancer or with no further cancer progression. Breast cancer is called metastatic when it has spread from the breast to other parts of the body such as the lymph nodes, lungs,...

Read More

Isolated cancer cells in lymph nodes increase the risk of the cancer re-occurring after surgery: A method to detect these isolated cells

Isolated cancer cells in lymph nodes increase the risk of the cancer re-occurring after surgery: A method to detect these isolated cells

Posted by on Feb 24, 2013 in Colorectal cancer | 0 comments

Colorectal cancer is the uncontrolled growth of cells in the rectum, colon (the large intestine) and it can also affect the appendix. It affects both men and women. Patients who are diagnosed with stage 1 and 2 colorectal cancer (cancers affecting the lining of the intestines – stage 1, and the muscle wall – stage 2) are generally only...

Read More